On September 3, 2025 Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, reported it will present new pre-clinical NSCLC data for its lead drug candidate, IAM1363, at the IASLC 2025 World Conference on Lung Cancer (Press release, Iambic Therapeutics, SEP 3, 2025, View Source [SID1234655747]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IAM1363 is a potent, irreversible Type II HER2 inhibitor, highly differentiated by its target selectivity (>5,000-fold HER2 vs EGFR selectivity), brain-penetrance, pan-mutant activity, and tumor enrichment. New IAM1363 data show potent anti-tumor activity and significant tumor regression across a panel of HER2-amplified and HER2-mutant NSCLC models, including greater anti-tumor activity compared to currently approved therapies. Importantly, IAM1363 demonstrated robust anti-tumor activity with prolonged survival in an intracranial model of brain metastasis. Finally, treatment with IAM1363 resulted in striking tumor enrichment in a HER2 exon 20-mutant NSCLC model with strong tumor regression.

IAM1363 is currently advancing in an ongoing Phase 1/1b clinical trial.

Poster: IAM1363 Is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Session and Presentation: Tumor Biology – Translational Biology, #P3.03.29

Presenter: John Huang, PhD, VP of Biology, Iambic Therapeutics

Time and Location: Tuesday, September 9, 2025, 10:00 AM CEST, Fira de Barcelona Convention Center, Exhibit Hall